AbbVie expands bispecific cancer drug push with up to $2.5 billion deal with Germany's Disco
ABBV•AbbVie agreed to pay Disco Pharmaceuticals $40 million upfront and up to $2.5 billion in milestone payments to develop AND-gated bispecific treatments for solid tumors. Disco will conduct research and discovery, and AbbVie can exclusively license selected programs for further development.
1. Deal terms
AbbVie agreed to pay up to $2.54 billion to develop cancer treatments with Germany-based private biotech Disco Pharmaceuticals. Disco will receive $40 million upfront, up to $2.5 billion in milestone payments and tiered royalties on worldwide net sales.
2. Research and licensing
Disco will handle research and discovery, while AbbVie can exclusively license selected programs for further development after specified research is completed. The early-stage deal does not specify how many programs may be covered or when any could enter clinical development.
3. Targeting cancer cells
The AND-gated bispecific approach is designed to recognize cancer cells only when two target proteins are present simultaneously, potentially reducing damage to healthy tissue. Disco has been developing therapies for small-cell lung and colorectal cancer, and CEO Mark Manfredi said the company aims to select a development candidate in the second half of next year.




